Lumos Diagnostics Inks Distribution Agreement With Henry Schein Subsidiary

California-based, Lumos Diagnostics Ltd (ASX:LDX) has entered into an agreement with Regional Health Care Group (RHCG), a subsidiary of Henry Schein, to distribute the FebriDx® point-of-care (POC) test in Australia and New Zealand.

FebriDx is a rapid POC test that distinguishes between viral and bacterial acute respiratory infections, providing results within 10 minutes from a fingerstick blood sample.

Importantly, Nasdaq-listed Henry Schein is the world’s largest provider of healthcare solutions to office-based dental and medical practitioners.

Regional Health Care Group is Henry Schein’s Medical business in Australia and New Zealand.

About the test

FebriDx test aids in the swift and accurate management of infectious patients across various settings, including primary care, urgent care, emergency departments, paediatric, and other outpatient environments.

Regional Health Care Group will sell the FebriDx test throughout Australia and New Zealand with sales and marketing kicking off immediately.

Lumos CEO Doug Ward said: “With our recent U.S. launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers.

“It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.”.

About Henry Schein

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories.

The company´s business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently.

These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.



JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.